Skip to main content
Clinical Trials/NCT01735331
NCT01735331
Completed
Not Applicable

Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss

Bagcilar Training and Research Hospital1 site in 1 country30 target enrollmentNovember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Recurrent Pregnancy Loss Without Current Pregnancy
Sponsor
Bagcilar Training and Research Hospital
Enrollment
30
Locations
1
Primary Endpoint
The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The aim of this study is determine vascular endothelial growth factor levels and angiogenesis/vascularity from hysteroscopic endometrial biopsies which taken from patients who has Recurrent Pregnancy Loss.The endometrial vascular endothelial growth factor levels will be measured by immunohistochemical staining methods due to office hysteroscopic endometrial biopsy after the menstruation at follicular phase of menstrual cycle.

Detailed Description

This study is a prospective,observational,single-center study.Ethical approval was obtained from the Institutional Review Board.This study will be completed 30 patients with Habitual Abortus. Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1) antibody kits. All assays will be performed according to the manufacturer's instructions.

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
August 2013
Last Updated
10 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Bagcilar Training and Research Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with Recurrent Pregnancy Loss who accept to join the study.

Exclusion Criteria

  • Patients whose age of \<18 and \>45
  • Patients with have any pregnancy.

Outcomes

Primary Outcomes

The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss

Time Frame: 3 months

Study Sites (1)

Loading locations...

Similar Trials